Electrotherapy for dental implants

​

In Situ electrochemical repassivation therapy of titanium dental implants can restore corrosion resistance and enhance cellular biocompatibility.


Invention Summary:

Peri-implantitis affects up to 25% of dental implant patients and is a leading cause of implant failure, representing a global market burden exceeding $1B annually. Current treatments focus on decontamination but fail to address the underlying material failure of titanium implants: progressive corrosion driven by inflammation. The present gold standard antimicrobial treatments fail to treat >50% of cases highlighting a substantial unmet clinical need and positioning the field as a strong candidate for FDA Breakthrough Device designation.

Rutgers researchers have developed a first-in-class, in situ electrochemical medical device that restores titanium surface integrity. By enabling in situ repair of the implant’s passivation layer, the device significantly improved anti-corrosion performance, effectively hindering titanium degradation to alleviate the corrosion-inflammation cycle of titanium dental implants.

Market Applications:

  • Treatment and management of peri-implantitis in dental patients
  • Maintenance and longevity enhancement of titanium dental implants
  • Advanced implant care from dental clinics and oral healthcare providers

Advantages:

  • Only therapy that directly restores the titanium oxide passivation layer in vivo
  • Interrupts the corrosion–inflammation cycle rather than treating symptoms
  • Chairside procedure compatible with all existing titanium implant systems
  • The technology is positioned for translational development toward chairside clinical use, with a clear regulatory and commercialization pathway in implant dentistry

 

Proof of Concept & Validation:

  • Demonstrated restoration of titanium corrosion resistance under inflammatory conditions
  • Proved cellular biocompatibility following in situ electrochemical repassivation according to ISO standards
  • Supported by preclinical data from a leading academic implantology group

Intellectual Property & Development Status: PCT application filed. Patent pending. Available for licensing and/or research collaboration. For any business development and other collaborative partnerships, contact:  marketingbd@research.rutgers.edu

Patent Information:
Licensing Manager:
Ryan Escolin
Licensing Manager, Life Sciences
Rutgers, The State University of New Jersey
848-932-4566
nescolin@research.rutgers.edu
Business Development:
Eusebio Pires
Senior Manager, Technology Marketing & Business Development
Rutgers, The State University of New Jersey
ep620@research.rutgers.edu
Keywords: